Aclaris stock soars for second day on licensing deal, analyst upgrades
| ACRS Stock | USD 4.07 0.25 6.54% |
Slightly above 55% of Aclaris Therapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aclaris Therapeutics stock suggests that some investors are interested at this time. Aclaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Aclaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
Aclaris |
Aclaris soared 60 percent Tuesday, the day after the company announced it was licensing two drug candidates, prompting upgrades by Piper Sandler, BTIG, Jefferies and Leerink.
Read at seekingalpha.com
 |
Aclaris Therapeutics Fundamental Analysis
We analyze Aclaris Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Aclaris Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Aclaris Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aclaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics with similar companies.
Peers
Aclaris Therapeutics Related Equities
| PRE | Prenetics Global | 1.13 | ||||
| BDSX | Biodesix | 0.70 | ||||
| SHC | Sotera Health | 0.53 | ||||
| MEDP | Medpace Holdings | 0.49 | ||||
| NEOG | Neogen | 0.28 | ||||
| MYGN | Myriad Genetics | 0.06 | ||||
| IQV | IQVIA Holdings | 0.29 | ||||
| CSTL | Castle Biosciences | 0.53 | ||||
| QGEN | Qiagen NV | 0.73 | ||||
| RDNT | RadNet | 0.88 | ||||
| ICLR | ICON PLC | 1.22 |
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.